Guardion Health Sciences - GHSI Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Guardion Health Sciences in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GHSI shares.
View GHSI analyst ratings or view top-rated stocks.

2 analysts have issued 1 year price targets for Guardion Health Sciences' stock. Their GHSI share price forecasts range from $0.60 to $0.75. On average, they predict the company's share price to reach $0.68 in the next year. This suggests that the stock has a possible downside of 86.2%.
View analysts price targets for GHSI or view top-rated stocks among Wall Street analysts.

Guardion Health Sciences' stock was trading at $0.1451 at the start of the year. Since then, GHSI shares have increased by 3,277.0% and is now trading at $4.90.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023.
View our GHSI earnings forecast.

Guardion Health Sciences, Inc. (NASDAQ:GHSI) issued its earnings results on Monday, August, 12th. The company reported ($0.84) EPS for the quarter. The firm earned $0.26 million during the quarter. Guardion Health Sciences had a negative net margin of 187.52% and a negative trailing twelve-month return on equity of 32.56%.

Shares of Guardion Health Sciences reverse split before market open on Monday, March 1st 2021. The 1-6 reverse split was announced on Friday, February 26th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 26th 2021. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Guardion Health Sciences investors own include iBio (IBIO), Biocept (BIOC), Onconova Therapeutics (ONTX), Heat Biologics (HTBX), VBI Vaccines (VBIV), Inovio Pharmaceuticals (INO), Ocugen (OCGN), Tonix Pharmaceuticals (TNXP), Co-Diagnostics (CODX) and FuelCell Energy (FCEL).

(GHSI) raised $6 million in an initial public offering (IPO) on Friday, April 5th 2019. The company issued 1,500,000 shares at a price of $4.00 per share. WallachBeth Capital and Westpark Capital served as the underwriters for the IPO.

Guardion Health Sciences trades on the NASDAQ under the ticker symbol "GHSI."

Guardion Health Sciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (135.83%) and Millennium Management LLC (15.97%). Insiders that own company stock include Bradley Louis Radoff and Bret Scholtes.
View institutional ownership trends.

Shares of GHSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GHSI stock can currently be purchased for approximately $4.90.

Guardion Health Sciences (NASDAQ:GHSI) has a market capitalization of $6.03 million and generates $7.23 million in revenue each year. The company earns $-24,750,000.00 in net income (profit) each year or ($36.50) on an earnings per share basis.

Guardion Health Sciences' mailing address is 15150 AVENUE OF SCIENCE SUITE 200, SAN DIEGO CA, 92128. The official website for the company is www.guardionhealth.com. The company can be reached via phone at (800) 873-5141, via email at matthew@plrinvest.com, or via fax at 858-630-5543.